Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease

Current Gastroenterology Reports

Volumn 6, Issue 6, 2004, Pages 447-453

  Chang, Stephen Y ^a   Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NITRIC OXIDE DONOR; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ENTEROPATHY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; LOW BACK PAIN; LOW DRUG DOSE; META ANALYSIS; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PEPTIC ULCER; PRESCRIPTION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY PREVENTION; STOMACH INJURY; STOMACH OBSTRUCTION; STOMACH PERFORATION; STOMACH PROTECTION; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT; VOMITING;

EID: 9944244963     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0066-6     Document Type: Review

References (32)

1. Peterson WL, Cryer B: Cox-1-sparing NSAIDs: Is the enthusiasm justified? JAMA 1999, 282:1961-3.
2. Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
3. Hawkey C, Laine L, Simon T: Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000, 43:370-377.
4. Hayden M, Pignone M, Phillips C, et al.: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:161-172.
5. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999, 117:17-25.
6. Sorenson HT, Mellemkjaer L, Blot WJ, et al.: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin Am J Gastroenterol 2000, 95:2218-2224.
7. Laine L, Harper S, Simon T, et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117: 76-783.
8. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999, 282:1921-1928.
9. Bombardier C, Laine L, Reicin A, et al.: The VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
10. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
11. Laine L, Bombardier C, Hawkey CJ, et al.: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 006-1012.
12. Bjarnason I, Takeuchi K, Simpson R: NSAIDs: the Emperor's new dogma? Gut 2003, 52:1376-1378.
13. Sigthorsson G, Simpson RJ, Walley M, et al.: COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice Gastroenterology 2002, 122:1913-1923.
14. Hunt RH, Harper S, Watson DJ, et al.: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events Am J Gastroenterol 2003, 98:1725-1733.
15. Rahme E, Bardou M, Dasgupta K, et al.: Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Gastroenterology 2004, 126: -1-A-2.
16. Arthritis Pain Society: Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. Baltimore, MD: APS; 2002.
17. Laine L: Approaches to NSAID use in the high-risk patient Gastroenterology 2001, 120:594-606.
18. Singh G: Recent considerations in nonsteroidal anti-inflammatory gastropathy. Am J Med 1998, 105:31S-38S.
19. Goldstein JL, Zhao SZ, Burke TA, et al.: Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States. Am J Gastroenterol 2003, 98: 627-2634.
20. Spiegel BMR, Targownik L, Dulai GS, et al.: The cost-effectiveness of cydooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Mad 2003, 138: 95-800
21. Laine L, Wogen J, Yu H: Gastrointestinal health care resource utilization with chronic use of cox-2 specific inhibitors versus traditional NSAIDs. Gastroenterology 2003, 125:389-395.
22. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998, 338: 27-734.
23. Yeomans ND, Tulassay Z, Juhasz L, et al. for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998, 338:719-726.
24. Serrano P, Lanas A, Arroyo MT, et al.: Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002, 16:1945-1953.
25. Lanas A, Rodrigo L, Marquez JL: Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDs and omeprazole. Scand J Gastroenterol 2003 38:693-700.
26. Sturkenboom MCJM, Burke TA, Tangelder MJD, et al.: Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmarcol Ther 2003, 18:1137-1147.
27. Sturkenboom MCJM, Burke TA, Dieleman JP, et al.: Underutilization of preventive strategies in patients receiving NSAIDs Rheumatology 2003, 42(Suppl 3):iii23-iii31.
28. Goldstein JL, Johanson J, Hawkey CJ, et al.: The comparative healing of gastric ulcers with esomeprazole versus ranitidine in patients taking either continuous cox-2 selective NSAIDs or non-selective NSAIDs. Gastroenterology 2004, 126:A-610.
29. Scheiman JM, Vakil N, Hawkey CJ, et al.: Esomeprazole prevents gastric and duodenal ulcers in at-risk patients on continuous non-selective or cox-2 selective NSAID therapy. Gastroenterology 2004, 126:A-82.
30. Fiorucci S, Santucci L, Gresele P, et al.: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124:600-607.
31. Mann NS: No-Aspirin (NCX 4016). Gastroenterology 2003, 125:1918-1919.
32. Hawkey CJ, Jones JI, Atherton CT, et al.: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003, 52:1537-1542.